Tricuspid Valve Repair Market

Tricuspid Valve Repair Market Size and Share:

The global tricuspid valve repair market size was valued at USD 717.50 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 1,291.62 Million by 2033, exhibiting a CAGR of 6.41% from 2025-2033. North America currently dominates the market, holding a market share of over 40.0% in 2024. The market is primarily driven by the increased use of minimally invasive TEER procedures, significant advancements in AI for diagnosis and patient selection, and the rapid growth of clinical trials and innovative device development, offering more effective treatments and better patient outcomes.

The global market is growing due to rising valvular heart disease cases, particularly among aging populations with heart failure and pulmonary hypertension. In line with this, improved diagnosis, advanced imaging, real-time monitoring, and increasing investments in minimally invasive repair techniques further drive tricuspid valve repair market growth. For instance, on May 24, 2024, the British Heart Foundation awarded EUR 4 Million to The University of Manchester, matched by the university for a total EUR 8 Million cardiovascular research investment. The funding supports studies on congenital heart disease, genetic drivers of chronic conditions, heart failure, inflammation links, and AI-driven disease prevention. Furthermore, the growing demand for personalized treatment approaches and patient-specific valve repair solutions further stimulates market appeal. Besides this, favorable reimbursement policies and increasing adoption of robotic-assisted procedures are bolstering expansion and efficiency in the market.

The United States stands out as a key regional market and is growing due to increasing adoption of transcatheter procedures, reducing surgical risks for high-risk patients. Similarly, regulatory approvals for innovative devices drive market expansion. Furthermore, rising obesity, hypertension, and metabolic disorders increase tricuspid regurgitation prevalence, augmenting the need for effective interventions. In addition to this, strong reimbursement frameworks and Medicare coverage improve accessibility of the product. Moreover, advanced cardiac centers, robotic-assisted interventions, and AI-driven diagnostics further strengthen tricuspid valve repair market demand. Notably, on March 12, 2024, Emory University Hospital launched its USD 87.7 Million Heart & Vascular expansion, featuring a 16-bed CV-ICU, advanced ORs, cath labs, EP labs, and robotic capabilities. Enhancing patient access and collaboration, this expansion reinforces Emory’s leadership in cardiac innovation and multidisciplinary care, advancing cutting-edge cardiovascular treatments.

Tricuspid Valve Repair Market Trends:

Rising Adoption of Transcatheter Edge-to-Edge Repair (TEER) Procedures

The market is experiencing a notable shift toward minimally invasive transcatheter edge-to-edge repair (TEER) procedures, driven by the rising prevalence of tricuspid regurgitation (TR) and the limitations of traditional surgical interventions. According to the American Heart Association, TR affects 5% to 20% of U.S. adults, often coexisting with mitral or aortic valve disease. Isolated TR (iTR) is now recognized as an independent condition, posing significant management challenges that necessitate improved treatment strategies. As part of tricuspid valve repair market trends, TEER is emerging as the preferred approach for high-risk patient’s ineligible for open-heart surgery, enhancing patient outcomes and reducing hospital stays. Recent advancements in clip-based devices and catheter-based techniques have improved procedural success rates. With growing regulatory approvals, increasing physician training, and a greater focus on minimally invasive solutions, TEER is poised to dominate the tricuspid valve repair market worldwide.

Integration of Artificial Intelligence (AI) in Diagnosis and Patient Selection

Artificial intelligence (AI) is revolutionizing the market by enhancing diagnostic accuracy, patient selection, and procedural planning. AI-powered imaging tools like echocardiography and cardiac MRI enable precise assessment of tricuspid regurgitation, ensuring timely interventions. As on August 22, 2024, AISAP received FDA 510(k) clearance for its AI-driven point-of-care ultrasound platform, AISAP CARDIO, which aids in diagnosing structural heart diseases. The cloud-based system, trained on 24 million echo video clips, empowers non-cardiologists to render rapid, accurate diagnoses. Machine learning models help clinicians identify ideal candidates for transcatheter and surgical interventions. Additionally, AI-powered predictive analytics improve long-term monitoring, detecting complications early. As AI adoption grows, its role in optimizing decision-making and procedural efficiency is expected to increase, expanding the tricuspid valve repair market share and driving innovation in heart valve technologies.

Expansion of Clinical Trials and Novel Device Development

The market is experiencing rapid growth driven by clinical trials and innovative device development, addressing the historical lack of dedicated repair solutions. As the impact of tricuspid regurgitation on morbidity and mortality gains recognition, manufacturers are investing in advanced transcatheter repair systems, including leaflet repair, annuloplasty rings, and chordal replacement techniques. For example, on May 6, 2024, Thubrikar Aortic Valve announced successful results with its Precision 2 Delivery Catheter in the first two patient implants of the Optimum Transcatheter Aortic Valve (Optimum TAV), which shows superior valve performance and durability. Ongoing clinical trials are evaluating emerging devices, paving the way for expanded treatment options. Strategic collaborations between research institutions and industry leaders are accelerating innovation. With increasing regulatory approvals, the tricuspid valve repair market outlook points to more effective and durable solutions reshaping the global landscape.

Tricuspid Valve Repair Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global tricuspid valve repair market, along with forecast at the global, regional, and country levels from 2025-2033. The market has been categorized based on indication and end user.

Analysis by Indication:

• Tricuspid Valve Regurgitation
• Tricuspid Valve Stenosis

Tricuspid valve regurgitation stands as the largest segment in 2024, holding around 84.7% of the market due to its high prevalence and increasing diagnosis rates. Continual advancements in imaging technologies and minimally invasive repair techniques have improved early detection and treatment. Rising cases of heart failure, pulmonary hypertension, and atrial fibrillation contribute to higher demand for tricuspid valve interventions. Additionally, the growing adoption of transcatheter tricuspid valve repair (TTVR) devices and improved patient outcomes further drive market dominance. Increasing awareness, expanded indications for intervention, and an aging population further solidify tricuspid valve regurgitation as the leading segment in this market.

Analysis by End User:

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Others

Hospitals lead the market with around 85.2% of market share in 2024 attributed to their advanced infrastructure, specialized cardiac units, and availability of skilled healthcare professionals. The increasing number of tricuspid valve regurgitation cases requiring surgical or transcatheter interventions drives hospital admissions. Hospitals offer comprehensive patient management, post-procedure monitoring, and access to advanced imaging technologies, ensuring superior treatment outcomes. Additionally, the growing preference for minimally invasive procedures, rising healthcare expenditures, and expanding reimbursement coverage support hospital-based treatments. Higher patient trust, well-equipped operating rooms, and multidisciplinary care further reinforce hospitals as the leading segment in this market.

Regional Analysis:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

In 2024, North America accounted for the largest market share of over 40.0% propelled by the developed healthcare infrastructure, heightened adoption of minimally invasive procedures, and increasing prevalence of tricuspid valve regurgitation. The region benefits from strong research and development (R&D) investments, favorable reimbursement policies, and access to innovative transcatheter repair technologies. A growing elderly population with cardiovascular diseases further drives demand for valve repair interventions. Additionally, the presence of key market players, rising awareness, and a high number of specialized cardiac centers enhance market growth. Government initiatives supporting early diagnosis and treatment further solidify North America's dominance in this sector.

Key Regional Takeaways:

United States Tricuspid Valve Repair Market Analysis

In 2024, the United States accounts for 86.70% of the North America tricuspid valve repair market driven by the increasing prevalence of heart failure cases. According to reports, approximately 6.7 million Americans over 20 have heart failure as of 2024, according to heart failure epidemiology and outcomes statistics. This number is expected to increase to 8.7 million by 2030, 10.3 million by 2040, and an astounding 11.4 million by 2050. Heart failure, particularly in aging populations, is becoming more common, leading to a higher demand for effective treatments like tricuspid valve repair. The rise in heart failure cases has prompted healthcare providers to prioritize innovative solutions that improve patient outcomes and quality of life. As patients seek advanced procedures to address valve dysfunction and prevent further complications, the adoption of tricuspid valve repair continues to gain momentum. This trend is reinforced by the integration of minimally invasive techniques, which offer shorter recovery times and lower surgical risks. Additionally, the advancement of medical technologies and ongoing research into more effective interventions further drives the growth in tricuspid valve repair adoption in the country.

Europe Tricuspid Valve Repair Market Analysis

In Europe, the growing adoption of tricuspid valve repair is largely driven by the region's aging population. According to WHO, in the WHO European Region, the number of people 60 and older is increasing quickly. There were 215 million in 2021, 247 million in 2030, and more than 300 million in 2050. With a significant portion of the European population now entering older age groups, the prevalence of cardiovascular diseases, including tricuspid valve dysfunction, is on the rise. This demographic shift heightened the demand for medical procedures that address valve-related conditions and improve the quality of life for elderly patients. As the population continues to age, healthcare systems across Europe are increasingly focusing on offering advanced cardiac care solutions, including tricuspid valve repair, to address the specific needs of older patients. Innovations in minimally invasive techniques and improvements in surgical outcomes further enhance the appeal of tricuspid valve repair, contributing to its adoption in the region.

Asia Pacific Tricuspid Valve Repair Market Analysis

In the Asia-Pacific region, the adoption of tricuspid valve repair is increasingly being fueled by rising healthcare expenditure. According to Economic Survey 2022-23, India's public expenses on healthcare touched 2.1 % of GDP in FY23 and 2.2% in FY22, against 1.6% in FY21. As countries within the region experience economic growth, they are allocating more resources toward improving healthcare infrastructure and access to advanced treatments. This increase in healthcare spending supports the expansion of medical technologies, making procedures like tricuspid valve repair more accessible to a larger segment of the population. With improvements in healthcare services and the rise of specialized cardiac centers, the demand for effective solutions to treat tricuspid valve disease has increased. The growing awareness of heart-related health issues and the availability of advanced procedures contribute to a more widespread adoption of tricuspid valve repair as part of comprehensive cardiovascular care.

Latin America Tricuspid Valve Repair Market Analysis

In Latin America, the implementation of tricuspid valve repair is on an increase due to the rise in rates of cardiovascular diseases (CVD). Studies estimate that mortality associated with CVD and stroke among men and women in Latin America will rise by 145% from 1990 to 2020. As the occurrence of heart disorders continues to grow, the number of people who require effective interventions like tricuspid valve repair has also risen. The burden of CVD in the region is becoming alarming, increasing the need for hospitals to have an improved care system for patients through advanced cardiac procedures. The rationale behind tricuspid valve repair includes patients with heart failure-related valve dysfunction and other cardiovascular conditions, hence encouraging the procedure to be adopted in Latin America. The emphasis on dealing with the cardiovascular health issues in the region continues to increase this form of acceptance.

Middle East and Africa Tricuspid Valve Repair Market Analysis

The increasing number of hospital facilities in the Middle East and Africa is driving the growth in the adoption of tricuspid valve repair. Dubai Healthcare City Authority report shows that the healthcare sector in Dubai has been growing at a rapid pace. By 2022, it had 4,482 private medical facilities and 55,208 licensed professionals, which are expected to increase by 3-6% in facilities and 10-15% in professionals in 2023. As the health care systems expand, more hospitals are offering specialized services, including heart valve surgeries. The development of medical infrastructure coupled with improved accessibility in healthcare delivery systems is building a scenario under which advanced treatment procedures such as tricuspid valve repair can become more common. This development will be useful for the area, as rising facilities in the hospital allow more management of the area's increasing cases of cardiovascular disease. As more facilities are built and upgraded, the accessibility and adoption of tricuspid valve repair will continue to grow.

Competitive Landscape:

The tricuspid valve repair market is highly competitive, driven by continuous technological advancements and regulatory approvals. Major medical device companies invest in research to develop innovative transcatheter repair solutions, enhancing procedural safety and efficacy. Strategic collaborations, mergers, and acquisitions strengthen market positioning and expand global reach. Notably, on July 1, 2024, in order to overcome existing system constraints, Anteris Technologies and v2vmedtech unveiled the concept lock of VClip, a next-generation Transcatheter Edge-to-Edge Repair (TEER) device for mitral and tricuspid valve regurgitation. Increasing clinical trials for novel devices enhance market growth, while FDA and CE approvals accelerate commercialization. Customization of valve repair solutions for diverse patient profiles fosters product differentiation. Emerging startups drive market innovation, while hospital and healthcare provider partnerships further expand market accessibility.

The report provides a comprehensive analysis of the competitive landscape in the tricuspid valve repair market with detailed profiles of all major companies, including:

• Abbott Laboratories
• Corcym UK Limited
• Edwards Lifesciences Corporation
• Labcor Laboratórios Ltda.
• Medtronic plc,

Latest News and Developments:

• January 2025: P&F USA received FDA approval to expand the TRICAV I study for the TricValve® Transcatheter Bicaval Valve System, increasing the trial size from 15 to 50 patients across 50 US sites. This single-arm clinical trial aims to assess the system's effectiveness in treating severe Tricuspid Regurgitation (TR) through a minimally invasive transcatheter procedure. The expansion follows promising initial results from compassionate use and earlier approvals in the US and Canada.
• October 2024: Englewood Health is among the first centers in New Jersey to use the FDA-approved transcatheter tricuspid valve replacement with the EVOQUE system, a minimally invasive technique to address severe tricuspid regurgitation. While most patients were told they had few options other than a heart transplant or an open-heart surgery, such a revolutionary advancement allows Dr. Joseph De Gregorio, executive director of cardiovascular services, to treat even the sickest patients.
• August 2024: UCI Health introduced transcatheter tricuspid valve replacement in Southern California, expanding its cardiovascular care options. Led by Dr. Antonio H. Frangieh, the procedure offers a minimally invasive alternative for heart valve failure. The FDA-approved device, introduced in February 2024, has already benefited four patients with positive results. UCI Health aims to lead in heart health innovations through its structural heart program.
• April 2024: Abbott won FDA approval for its first-of-its-kind TriClip device meant to fix leaky tricuspid valves. The minimally invasive treatment offers a safe alternative to surgery for patients who are unable to undergo the surgical procedure. Data from the clinical trials indicates that patients treated with TriClip have shown great improvements in their symptoms and quality of life. About 1.6 million Americans suffer from tricuspid regurgitation, which negatively affects their quality of life.
• February 2024: The FDA approved Edwards Lifesciences' Evoque tricuspid valve replacement system for treating tricuspid regurgitation (TR), marking the first approval of a transcatheter tricuspid device in the U.S. The approval follows promising results from the TRISCEND II trial, which showed significant improvement in TR grade and functional status for patients with severe TR. Dr. Susheel Kodali, lead investigator, highlighted the valve's potential to virtually eliminate TR in a broad patient population.

Tricuspid Valve Repair Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the tricuspid valve repair market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global tricuspid valve repair market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's Five Forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the tricuspid valve repair industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.